ANI Pharma Looks to Buy A Platform For Its Push Into Injectables
Having swelled its pipeline of US injectable drugs through an acquisition, ANI Pharmaceuticals is on the lookout for attractive manufacturing assets.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
In a deal worth up to $77.5m, ANI has acquired rights to 12 marketed generics in the US, as well as to another 11 pipeline products, from Amerigen.
Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.